Immediate Impact
5 hit
Citing Papers
Immunology and immunotherapy of cholangiocarcinoma
2023 Hit
Gallbladder cancer
2022 Hit
Works of Akinori Asagi being referenced
Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
2019